Three Seasons Wealth LLC Has $1.68 Million Position in Exelixis, Inc. $EXEL

Three Seasons Wealth LLC decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 48.2% in the second quarter, Holdings Channel reports. The firm owned 30,814 shares of the biotechnology company’s stock after selling 28,705 shares during the quarter. Three Seasons Wealth LLC’s holdings in Exelixis were worth $1,677,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in EXEL. Motiv8 Investments LLC bought a new position in shares of Exelixis during the 4th quarter worth approximately $26,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Exelixis during the first quarter valued at $27,000. Acumen Wealth Advisors LLC acquired a new stake in shares of Exelixis in the 4th quarter valued at $29,000. Western Wealth Management LLC acquired a new position in Exelixis in the first quarter valued at about $29,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 773 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EXEL. Zacks Research raised shares of Exelixis from a “strong sell” rating to a “hold” rating in a research note on Tuesday. UBS Group set a $55.00 price objective on Exelixis in a report on Monday, August 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 target price on shares of Exelixis in a research note on Thursday, July 2nd. Leerink Partners lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 target price on the stock. in a report on Thursday, August 6th. Finally, Truist Financial decreased their price target on shares of Exelixis from $56.00 to $52.00 and set a “hold” rating for the company in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Exelixis currently has an average rating of “Hold” and a consensus price target of $50.07.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from “Strong Sell” to “Hold,” improving the tone around the stock. Exelixis is a Top-Ranked Value Stock
• Positive Sentiment: Zacks Research modestly raised its EPS forecasts for Exelixis’ fourth quarter of 2027, second quarter of 2028 and full-year 2028. The FY2028 estimate increased to $4.21 from $4.18, suggesting slightly better long-term earnings expectations.
• Positive Sentiment: Exelixis has broken out to new highs following its earnings report, reflecting continued investor demand and favorable chart momentum. Exelixis Reaches New 52-Week High Following Analyst Upgrade
• Positive Sentiment: The company is being highlighted as a highly ranked value stock, which may attract investors seeking relatively attractive valuation and earnings potential.
• Neutral Sentiment: Investors are watching a potential FDA action tied to the cancer-treatment business. A favorable decision could provide another catalyst, while the timing and outcome remain uncertain. Cancer Stock Breaks Out to Highs
• Negative Sentiment: Despite beating quarterly EPS expectations, Exelixis’ latest revenue came in below consensus estimates. The earnings “snag” means investors may need evidence that growth can accelerate before the breakout is sustained. IBD Stock of the Day Exelixis Hits Earnings Snag and Then Breaks Out

Exelixis Stock Down 0.2%

NASDAQ:EXEL opened at $59.01 on Friday. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $59.72. The business has a 50 day moving average price of $55.07 and a two-hundred day moving average price of $49.50. The company has a market cap of $14.62 billion, a P/E ratio of 18.56, a price-to-earnings-growth ratio of 1.76 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The business had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. During the same quarter last year, the firm earned $0.75 earnings per share. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, analysts anticipate that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares in the company, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.